Walgreens shares pop on report pharmacy chain could sell itself to PE firm Sycamore

Walgreens shares pop on report pharmacy chain could sell itself to PE firm Sycamore


People walk by a Walgreens on November 3, 2024 in Brookline, Massachusetts.

Danielle DeVries | CNBC

Shares of Walgreens jumped nearly 25% on Tuesday on a report that the company is in talks to sell itself to private equity firm Sycamore Partners. 

Walgreens and Sycamore have been discussing a deal that could be completed early next year, The Wall Street Journal reported, citing people familiar with the matter.

A Walgreens spokesperson declined to comment on the reported talks.

The report comes during a rough period for the retail pharmacy giant. The company’s stock was down more than 60% for the year before its climb Tuesday.

Walgreens – squeezed by the transition out of the Covid pandemic, a leadership shakeup, pharmacy reimbursement pressure and its wobbly push into health-care – has underperformed Wall Street’s earnings expectations for two straight quarters.

In October, Walgreens said it plans to close roughly 1,200 of its drugstores over the next three years, which includes 500 in fiscal 2025 alone. Walgreens has around 8,700 locations in the U.S., a quarter of which it says are unprofitable. The company has also scaled back its push into primary care by cutting its stake in primary-care provider VillageMD. 

Walgreens has reportedly been seen as a potential private equity target in the past. 

In 2019, private equity firm KKR made a roughly $70 billion buyout offer to the company, the Financial Times and Bloomberg reported at the time. 

This is breaking news. Please refresh for updates.



Source

Healthy Returns: What to expect from pharma at the JPM conference
Health

Healthy Returns: What to expect from pharma at the JPM conference

Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]

Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Health

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]

Read More
Patient advocacy groups urge U.S. court to halt overseas prescription drug operations
Health

Patient advocacy groups urge U.S. court to halt overseas prescription drug operations

In a photo illustration, prescription drugs are seen next to a pill bottle on July 23, 2024 in New York. Spencer Platt | Getty Images News | Getty Images A coalition of patient advocacy groups is urging a federal court to halt the practices of third-party companies that buy drugs from countries outside the FDA-regulated […]

Read More